Drug Trial Radar · NCT03268902
Early Life Interventions for Childhood Growth and Development In Tanzania
Last checked: Nov 20, 2026Latest source record: May 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,188
Actual
Start
Sep 5, 2017
Primary completion
Feb 28, 2020
Study completion Mar 26, 2020
Sponsor
- Lead sponsor
- Haydom Lutheran HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Virginia; Bill and Melinda Gates Foundation
- First posted
- Aug 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 days, up to 14 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to assess growth and cognitive effects of treatment with azithromycin and nitazoxanide and/or nicotinamide (vitamin B3) supplementation nicotinamide.
Conditions
- Malnutrition
- Stunting
- Cognitive Development
- Enteric Pathogens
Interventions
Azithromycin Oral Liquid ProductDrug
Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
Nitazoxanide Oral SuspensionDrug
Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
NicotinamideDietary supplement
Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form. Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age
PlacebosDrug
Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months. Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form. Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age
Primary outcomes
What the sponsor says the trial is designed to measure.
- Height-for-age z-score (HAZ) at 18 monthsTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Haydom Lutheran Hospital
Haydom, Manyara Region, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.